” We stand by that statement today. Since no action was taken for a 2-year period, the case is now closed. The implication of this is that the patient’s legal team accepted our rebuttal and criticism of Dr Croft. We believe the patient suffered from parasitophobia, not cysticercosis. Under these circumstances, we were somewhat surprised to see the case published in an International Journal, particularly with the comment that the authors

“have no conflicts of interest.” Although Dr Croft does not name either of us, he refers to “two British specialists in tropical disease,” uses the word “misdiagnosed,” alleges that we “did not listen carefully to the patient’s history” and ordered tests of “low specificity” when he should be fully aware that we performed the EITB—not the ELISA as he alleges. In our judgment, his report is inaccurate and reaches the wrong conclusion Dabrafenib and as such should be either clarified or withdrawn. Tom Doherty 1 and Stephen Wright 1 “
“The article learn more by Jentes and colleagues[1] is a summary of current human rabies exposure management from the perspective of the developed world where biologicals are available, public health staff handle most rabies-exposed subjects

and mostly for free to the patients. The situation is different in rabies-endemic regions where rabies vaccines and immunoglobulins are often not available or affordable to the average citizen. The fear of

rabies, the adverse side effects from old brain-tissue-derived vaccines, the lengthy postexposure treatment schedules, and the dreadful death are Acetophenone still remembered. They discourage some patients from seeking professional help. This is particularly true in countries where World Health Organization (WHO)-level treatment is only available at private hospitals, which most victims cannot afford. The article by Sibunruang and colleagues[2] points out serious deficiencies in postexposure rabies management. It emphasizes the advisability for more travelers to rabies-endemic countries to obtain preexposure prophylaxis. Furthermore, the article discusses a new WHO-approved development in postexposure booster schedules for previously vaccinated persons with a new rabies exposure. It is an abbreviation of injections to four intradermal sites and one clinic visit, which produces higher antibody levels and saves much inconvenience for travelers replacing the former two clinic visits. One major reason for postexposure management deficiencies is the disregard for use of rabies immunoglobulins as recommended by WHO and others. Immunoglobulins are truly effective only when injected into and around bite wounds. It takes at least 1 week for the circulating antibody levels from the vaccine injections to reach sufficient levels to have virus-killing effects at the inoculation sites.